Dillard's, Inc. (DDS)
NYSE: DDS · Real-Time Price · USD
467.56
-1.90 (-0.40%)
At close: Aug 7, 2025, 4:00 PM
468.19
+0.63 (0.13%)
Pre-market: Aug 8, 2025, 4:58 AM EDT
Theseus Pharmaceuticals Stock Forecast
Stock Price Forecast
The 3 analysts that cover Theseus Pharmaceuticals stock have a consensus rating of "Sell" and an average price target of $359.33, which forecasts a -23.15% decrease in the stock price over the next year. The lowest target is $170 and the highest is $458.
Price Target: $359.33 (-23.15%)
Analyst Consensus: Sell
Analyst Ratings
The average analyst rating for Theseus Pharmaceuticals stock is "Sell". This means that analysts believe this stock is likely to lead to lower returns than market as a whole.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 1 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 2 | 2 | 2 | 2 | 2 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Sell Maintains $368 → $458 | Sell | Maintains | $368 → $458 | -2.04% | Jul 28, 2025 |
| Telsey Advisory Group | Telsey Advisory Group | Hold Maintains $450 | Hold | Maintains | $450 | -3.76% | May 16, 2025 |
| UBS | UBS | Strong Sell Maintains $150 → $170 | Strong Sell | Maintains | $150 → $170 | -63.64% | May 16, 2025 |
| UBS | UBS | Strong Sell Maintains $200 → $202 | Strong Sell | Maintains | $200 → $202 | -56.80% | Feb 28, 2025 |
| Telsey Advisory Group | Telsey Advisory Group | Hold Maintains $450 | Hold | Maintains | $450 | -3.76% | Feb 26, 2025 |
Financial Forecast
Revenue This Year
6.50B
from 6.59B
Decreased by -1.31%
Revenue Next Year
6.45B
from 6.50B
Decreased by -0.78%
EPS This Year
27.98
from 36.82
Decreased by -23.99%
EPS Next Year
22.76
from 27.98
Decreased by -18.66%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 6.9B | 7.0B | 6.2B |
| Avg | 6.5B | 6.5B | 6.0B |
| Low | 6.1B | 5.9B | 5.8B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 4.6% | 7.3% | -3.7% |
| Avg | -1.3% | -0.8% | -7.4% |
| Low | -7.1% | -8.8% | -10.2% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 32.81 | 27.51 | 16.07 |
| Avg | 27.98 | 22.76 | 15.45 |
| Low | 22.83 | 16.51 | 14.99 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -10.9% | -1.7% | -29.4% |
| Avg | -24.0% | -18.7% | -32.1% |
| Low | -38.0% | -41.0% | -34.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.